The initial indication of male puberty is the growth of the testicles. This typically happens between the ages of 9.5 and 13.5 years and is the first sign of male puberty. Testicular enlargement is the only pubertal change present in Tanner stage 1.

During Tanner stage 2, which usually occurs between the ages of 10.5 and 14.5 years, penis growth begins.

Pubic hair development also starts during Tanner stage 2, between the ages of 9.9 and 14.0 years.

The height growth spurt occurs at age 14 and reaches a maximum of 10cm/year in Tanner.

The voice changes during Tanner stage 3, which typically happens around 13.5 years old.

Puberty: Normal Changes in Males and Females

Puberty is a natural process that marks the transition from childhood to adolescence. In males, the first sign of puberty is testicular growth, which typically occurs around the age of 12. Testicular volume greater than 4 ml indicates the onset of puberty. The maximum height spurt for boys occurs at the age of 14. On the other hand, in females, the first sign of puberty is breast development, which usually occurs around the age of 11.5. The height spurt for girls reaches its maximum early in puberty, at the age of 12, before menarche. Menarche, or the first menstrual period, typically occurs at the age of 13, with a range of 11-15 years. Following menarche, there is only a slight increase of about 4% in height.

During puberty, it is normal for boys to experience gynaecomastia, or the development of breast tissue. Girls may also experience asymmetrical breast growth. Additionally, diffuse enlargement of the thyroid gland may be seen in both males and females. These changes are all part of the normal process of puberty and should not be a cause for concern.

The water deprivation test is a diagnostic tool used to assess patients with polydipsia, or excessive thirst. During the test, the patient is instructed to refrain from drinking water, and their bladder is emptied. Hourly measurements of urine and plasma osmolalities are taken to monitor changes in the body’s fluid balance. The results of the test can help identify the underlying cause of the patient’s polydipsia. Normal results show a high urine osmolality after the administration of DDAVP, while psychogenic polydipsia is characterized by a low urine osmolality. Cranial DI and nephrogenic DI are both associated with high plasma osmolalities and low urine osmolalities.

Sulfonylureas are a type of medication used to treat type 2 diabetes mellitus. They work by increasing the amount of insulin produced by the pancreas, but only if the beta cells in the pancreas are functioning properly. Sulfonylureas bind to a specific channel on the cell membrane of pancreatic beta cells, known as the ATP-dependent K+ channel (KATP).

While sulfonylureas can be effective in managing diabetes, they can also cause some adverse effects. The most common side effect is hypoglycemia, which is more likely to occur with long-acting preparations like chlorpropamide. Another common side effect is weight gain. However, there are also rarer side effects that can occur, such as hyponatremia (low sodium levels) due to inappropriate ADH secretion, bone marrow suppression, hepatotoxicity (liver damage), and peripheral neuropathy.

It is important to note that sulfonylureas should not be used during pregnancy or while breastfeeding.

The Role of Pregnenolone in Steroid Hormone Synthesis

In the production of steroid hormones in the human body, the conversion of cholesterol to pregnenolone is a crucial step. Pregnenolone serves as the precursor for all steroid hormones, and its formation is the limiting factor in the synthesis of these hormones. This conversion process occurs within the mitochondria of steroid-producing tissues. Essentially, the body needs to convert cholesterol to pregnenolone before it can produce any other steroid hormones. This highlights the importance of pregnenolone in the body’s endocrine system and its role in regulating various physiological processes.

Sulfonylureas bind to potassium-ATP channels on the cell membrane of pancreatic beta cells, mimicking the role of ATP from the outside. This results in the blocking of these channels, causing membrane depolarisation and the opening of voltage-gated calcium channels. As a result, insulin release is stimulated.

While acute use of sulfonylureas increases insulin secretion and decreases insulin clearance in the liver, it can also cause hypoglycaemia, which is the main side effect. This can lead to the serious complication of neuroglycopenia, resulting in a lack of glucose supply to the brain, causing confusion and possible coma. Treatment for this should involve oral glucose, intramuscular glucagon, or intravenous glucose.

Chronic exposure to sulfonylureas does not result in an acute increase in insulin release, but a decrease in plasma glucose concentration does remain. Additionally, chronic exposure to sulfonylureas leads to down-regulation of their receptors.

Sulfonylureas are a type of medication used to treat type 2 diabetes mellitus. They work by increasing the amount of insulin produced by the pancreas, but only if the beta cells in the pancreas are functioning properly. Sulfonylureas bind to a specific channel on the cell membrane of pancreatic beta cells, known as the ATP-dependent K+ channel (KATP).

While sulfonylureas can be effective in managing diabetes, they can also cause some adverse effects. The most common side effect is hypoglycemia, which is more likely to occur with long-acting preparations like chlorpropamide. Another common side effect is weight gain. However, there are also rarer side effects that can occur, such as hyponatremia (low sodium levels) due to inappropriate ADH secretion, bone marrow suppression, hepatotoxicity (liver damage), and peripheral neuropathy.

It is important to note that sulfonylureas should not be used during pregnancy or while breastfeeding.

Diagnosis and Symptoms of Hypothyroidism

Hypothyroidism is diagnosed through blood tests that show low levels of T4 and elevated levels of TSH. Physical examination may reveal slow relaxation of tendon jerks, bradycardia, and goitre. A bruit over a goitre is associated with Graves’ thyrotoxicosis, while palmar erythema and fine tremor occur in thyrotoxicosis. In addition to these common symptoms, hypothyroidism may also present with rarer features such as cerebellar features, compression neuropathies, hypothermia, and macrocytic anaemia. It is important to diagnose and treat hypothyroidism promptly to prevent further complications.

Clusters of microcalcification, known as psammoma bodies, are frequently observed in papillary carcinomas.

Thyroid cancer rarely causes hyperthyroidism or hypothyroidism as it does not usually secrete thyroid hormones. The most common type of thyroid cancer is papillary carcinoma, which is often found in young females and has an excellent prognosis. Follicular carcinoma is less common, while medullary carcinoma is a cancer of the parafollicular cells that secrete calcitonin and is associated with multiple endocrine neoplasia type 2. Anaplastic carcinoma is rare and not responsive to treatment, causing pressure symptoms. Lymphoma is also rare and associated with Hashimoto’s thyroiditis.

Management of papillary and follicular cancer involves a total thyroidectomy followed by radioiodine to kill residual cells. Yearly thyroglobulin levels are monitored to detect early recurrent disease. Papillary carcinoma usually contains a mixture of papillary and colloidal filled follicles, while follicular adenoma presents as a solitary thyroid nodule and malignancy can only be excluded on formal histological assessment. Follicular carcinoma may appear macroscopically encapsulated, but microscopically capsular invasion is seen. Medullary carcinoma is associated with raised serum calcitonin levels and familial genetic disease in up to 20% of cases. Anaplastic carcinoma is most common in elderly females and is treated by resection where possible, with palliation achieved through isthmusectomy and radiotherapy. Chemotherapy is ineffective.

The correct answer is low urine osmolality after both fluid deprivation and desmopressin. This is indicative of nephrogenic diabetes insipidus, a condition where the kidneys are insensitive to antidiuretic hormone (ADH), resulting in an inability to concentrate urine. This leads to low urine osmolality even during water deprivation and no response to desmopressin. High urine osmolality after both fluid deprivation and desmopressin would be seen in a healthy individual or primary polydipsia, while low urine osmolality after desmopressin but high after fluid deprivation is not commonly seen in any pathological state. Similarly, low urine osmolality after fluid deprivation but high after desmopressin is typically seen in cranial DI, which is not the best answer as the patient has no risk factors for this condition.

The water deprivation test is a diagnostic tool used to assess patients with polydipsia, or excessive thirst. During the test, the patient is instructed to refrain from drinking water, and their bladder is emptied. Hourly measurements of urine and plasma osmolalities are taken to monitor changes in the body’s fluid balance. The results of the test can help identify the underlying cause of the patient’s polydipsia. Normal results show a high urine osmolality after the administration of DDAVP, while psychogenic polydipsia is characterized by a low urine osmolality. Cranial DI and nephrogenic DI are both associated with high plasma osmolalities and low urine osmolalities.

Insulin stimulates the Na+/K+ ATPase pump, leading to a decrease in serum potassium levels. This is primarily achieved through increased activity of the sodium-potassium pump, which is triggered by phosphorylation of the transmembrane subunits in response to insulin. While calcium gluconate is used to protect the heart during hyperkalaemia-induced arrhythmias, it does not affect potassium levels. Although IV fluids can improve renal function and potassium clearance, they are not the primary method for reducing potassium levels. Calcium-activated potassium channels are present throughout the body and are activated by an increase in intracellular calcium levels during action potentials.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

During pregnancy, thyroid function can be affected, leading to a range of conditions. However, in the case of a patient with a nodular goitre, antithyroid antibodies are not a likely cause. Thyroglobulin levels may increase slightly in the final trimester, but this is not the primary issue. Similarly, while TSH levels may be raised in pregnancy, this is a secondary effect caused by an increase in TBG.

During pregnancy, there is an increase in the levels of thyroxine-binding globulin (TBG), which causes an increase in the levels of total thyroxine. However, this does not affect the free thyroxine level. If left untreated, thyrotoxicosis can increase the risk of fetal loss, maternal heart failure, and premature labor. Graves’ disease is the most common cause of thyrotoxicosis during pregnancy, but transient gestational hyperthyroidism can also occur due to the activation of the TSH receptor by HCG. Propylthiouracil has traditionally been the antithyroid drug of choice, but it is associated with an increased risk of severe hepatic injury. Therefore, NICE Clinical Knowledge Summaries recommend using propylthiouracil in the first trimester and switching to carbimazole in the second trimester. Maternal free thyroxine levels should be kept in the upper third of the normal reference range to avoid fetal hypothyroidism. Thyrotropin receptor stimulating antibodies should be checked at 30-36 weeks gestation to determine the risk of neonatal thyroid problems. Block-and-replace regimes should not be used in pregnancy, and radioiodine therapy is contraindicated.

On the other hand, thyroxine is safe during pregnancy, and serum thyroid-stimulating hormone should be measured in each trimester and 6-8 weeks postpartum. Women require an increased dose of thyroxine during pregnancy, up to 50% as early as 4-6 weeks of pregnancy. Breastfeeding is safe while on thyroxine. It is important to manage thyroid problems during pregnancy to ensure the health of both the mother and the baby.

The doll-like appearance of the boy in his presentation suggests that he may be suffering from growth hormone deficiency, which can cause short stature, forehead prominence, and maxillary hypoplasia. The hypothalamus controls the release of growth hormone through the pulsatile release of growth hormone releasing hormone. Therefore, measuring GHRH levels is not a useful method for investigating growth hormone deficiency.

Understanding Growth Hormone and Its Functions

Growth hormone (GH) is a hormone produced by the somatotroph cells in the anterior pituitary gland. It plays a crucial role in postnatal growth and development, as well as in regulating protein, lipid, and carbohydrate metabolism. GH acts on a transmembrane receptor for growth factor, leading to receptor dimerization and direct or indirect effects on tissues via insulin-like growth factor 1 (IGF-1), which is primarily secreted by the liver.

GH secretion is regulated by various factors, including growth hormone releasing hormone (GHRH), fasting, exercise, and sleep. Conversely, glucose and somatostatin can decrease GH secretion. Disorders associated with GH include acromegaly, which results from excess GH, and GH deficiency, which can lead to short stature.

In summary, GH is a vital hormone that plays a significant role in growth and metabolism. Understanding its functions and regulation can help in the diagnosis and treatment of GH-related disorders.

The Na+/K+ ATPase pump is stimulated by insulin, leading to a decrease in serum potassium levels. This effect is particularly relevant in patients with diabetic ketoacidosis, who experience insulin deficiency and hyperkalemia. It is important to monitor serum potassium levels closely during the management of diabetic ketoacidosis to avoid the potential complications of hypokalemia. Insulin does not cause a decrease in sodium levels, and its effects on calcium and phosphate homeostasis are minimal. The resolution of ketoacidosis with insulin and fluids will result in an increase in serum bicarbonate levels back to normal range.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

Corticosteroids are a class of medications commonly prescribed for various clinical uses, such as treating allergies, inflammatory conditions, auto-immunity, and endogenous steroid replacement.

There are different types of corticosteroids, each with varying levels of glucocorticoid and mineralocorticoid activity. Glucocorticoids mimic cortisol, which is involved in carbohydrate metabolism and the stress response, while mineralocorticoids mimic aldosterone, which regulates sodium and water retention in response to low blood pressure.

The clinical uses and side effects of corticosteroids depend on their level of glucocorticoid and mineralocorticoid activity. Fludrocortisone, for example, has minimal glucocorticoid activity and high mineralocorticoid activity.

Therefore, fluid retention is the most associated side effect with mineralocorticoid activity, while depression, hyperglycemia, osteoporosis, and peptic ulceration are side effects associated with glucocorticoid activity.

Corticosteroids are commonly prescribed medications that can be taken orally or intravenously, or applied topically. They mimic the effects of natural steroids in the body and can be used to replace or supplement them. However, the use of corticosteroids is limited by their numerous side effects, which are more common with prolonged and systemic use. These side effects can affect various systems in the body, including the endocrine, musculoskeletal, gastrointestinal, ophthalmic, and psychiatric systems. Some of the most common side effects include impaired glucose regulation, weight gain, osteoporosis, and increased susceptibility to infections. Patients on long-term corticosteroids should have their doses adjusted during intercurrent illness, and the medication should not be abruptly withdrawn to avoid an Addisonian crisis. Gradual withdrawal is recommended for patients who have received high doses or prolonged treatment.

Rheumatoid factor is not the most suitable answer for a patient with hypothyroidism, despite its presence in various rheumatological conditions and healthy individuals.

Understanding Thyroid Autoantibodies

Thyroid autoantibodies are antibodies that attack the thyroid gland, causing various thyroid disorders. There are three main types of anti-thyroid autoantibodies: anti-thyroid peroxidase (anti-TPO) antibodies, TSH receptor antibodies, and thyroglobulin antibodies. Anti-TPO antibodies are present in 90% of Hashimoto’s thyroiditis cases and 75% of Graves’ disease cases. TSH receptor antibodies are found in 90-100% of Graves’ disease cases. Thyroglobulin antibodies are present in 70% of Hashimoto’s thyroiditis cases, 30% of Graves’ disease cases, and a small proportion of thyroid cancer cases.

Understanding the different types of thyroid autoantibodies is important in diagnosing and treating thyroid disorders. Hashimoto’s thyroiditis and Graves’ disease are the most common autoimmune thyroid disorders, and the presence of specific autoantibodies can help differentiate between the two. Additionally, monitoring the levels of these antibodies can help track the progression of the disease and the effectiveness of treatment. Overall, understanding thyroid autoantibodies is crucial in managing thyroid health.

The two main factors that contribute to diabetic foot disease are loss of sensation and peripheral arterial disease. When reviewing a diabetic patient who presents with a complication, it is crucial to recognize that those with a loss of protective sensation are at a high risk of developing diabetic foot disease. Therefore, any ulcers must be promptly managed to prevent severe infection.

Out of the given options, the most appropriate next step in managing this patient is to conduct a full neurovascular examination of their lower limbs. While checking the HbA1C levels is important, it is not the immediate concern for this patient. Similarly, examining foot sensation using a 10g monofilament is a crucial step, but it is only a part of a comprehensive neurovascular examination. Measuring C-peptide is not relevant to the current situation.

Diabetic foot disease is a significant complication of diabetes mellitus that requires regular screening. In 2015, NICE published guidelines on diabetic foot disease. The disease is caused by two main factors: neuropathy, which results in a loss of protective sensation, and peripheral arterial disease, which can cause macro and microvascular ischaemia. Symptoms of diabetic foot disease include loss of sensation, absent foot pulses, reduced ankle-brachial pressure index (ABPI), intermittent claudication, calluses, ulceration, Charcot’s arthropathy, cellulitis, osteomyelitis, and gangrene.

All patients with diabetes should be screened for diabetic foot disease at least once a year. Screening for ischaemia involves palpating for both the dorsalis pedis pulse and posterial tibial artery pulse, while screening for neuropathy involves using a 10 g monofilament on various parts of the sole of the foot. NICE recommends that patients be risk-stratified into low, moderate, and high-risk categories based on factors such as deformity, previous ulceration or amputation, renal replacement therapy, and the presence of calluses or neuropathy. Patients who are moderate or high-risk should be regularly followed up by their local diabetic foot centre.

Diabetic ketoacidosis is depicted in this image. It is a critical condition that requires urgent attention, with a focus on administering insulin, fluid resuscitation, and closely monitoring potassium levels.

Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and breath that smells like acetone. Diagnostic criteria include glucose levels above 11 mmol/l or known diabetes mellitus, pH below 7.3, bicarbonate below 15 mmol/l, and ketones above 3 mmol/l or urine ketones ++ on dipstick.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Fluid replacement is necessary as most patients with DKA are deplete around 5-8 litres. Isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral edema. Children and young adults are particularly vulnerable to cerebral edema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations, headache, irritability, visual disturbance, focal neurology, etc.

Insulin is a hormone produced by the pancreas that plays a crucial role in regulating the metabolism of carbohydrates and fats in the body. It works by causing cells in the liver, muscles, and fat tissue to absorb glucose from the bloodstream, which is then stored as glycogen in the liver and muscles or as triglycerides in fat cells. The human insulin protein is made up of 51 amino acids and is a dimer of an A-chain and a B-chain linked together by disulfide bonds. Pro-insulin is first formed in the rough endoplasmic reticulum of pancreatic beta cells and then cleaved to form insulin and C-peptide. Insulin is stored in secretory granules and released in response to high levels of glucose in the blood. In addition to its role in glucose metabolism, insulin also inhibits lipolysis, reduces muscle protein loss, and increases cellular uptake of potassium through stimulation of the Na+/K+ ATPase pump.

The initial hormone response to hypoglycaemia is the secretion of glucagon. In the case of a suspected gliclazide overdose, the most likely presentation would be hypoglycaemia, as evidenced by the patient’s sudden onset of sweating, weakness, and confusion. Other medications ingested are unlikely to produce these symptoms. When the body experiences hypoglycaemia, it first reduces insulin production and then increases glucagon secretion, which promotes gluconeogenesis to raise blood glucose levels.

Glycogen synthase is an enzyme involved in glycogenesis, the process of converting glucose into glycogen for storage in the body. However, in the case of hypoglycaemia caused by gliclazide ingestion, the body would carry out gluconeogenesis to release glucose, rather than glycogenesis.

While cortisol is released in response to hypoglycaemia, it is a later response and is secreted after glucagon. Cortisol is a glucocorticoid hormone that also promotes gluconeogenesis and glucose production.

Glutathione is an antioxidant found in the liver that helps neutralize and eliminate the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) produced by paracetamol. In cases of paracetamol overdose, glutathione levels are depleted, but this patient’s symptoms are too acute for a paracetamol overdose. Liver failure resulting from paracetamol overdose takes several hours to develop and even longer before physical symptoms appear. The antidote treatment for paracetamol overdose is acetylcysteine, which replenishes glutathione levels.

Understanding Hypoglycaemia: Causes, Features, and Management

Hypoglycaemia is a condition characterized by low blood sugar levels, which can lead to a range of symptoms and complications. There are several possible causes of hypoglycaemia, including insulinoma, liver failure, Addison’s disease, and alcohol consumption. The physiological response to hypoglycaemia involves hormonal and sympathoadrenal responses, which can result in autonomic and neuroglycopenic symptoms. While blood glucose levels and symptom severity are not always correlated, common symptoms of hypoglycaemia include sweating, shaking, hunger, anxiety, nausea, weakness, vision changes, confusion, and dizziness. In severe cases, hypoglycaemia can lead to convulsions or coma.

Managing hypoglycaemia depends on the severity of the symptoms and the setting in which it occurs. In the community, individuals with diabetes who inject insulin may be advised to consume oral glucose or a quick-acting carbohydrate such as GlucoGel or Dextrogel. A ‘HypoKit’ containing glucagon may also be prescribed for home use. In a hospital setting, treatment may involve administering a quick-acting carbohydrate or subcutaneous/intramuscular injection of glucagon for unconscious or unable to swallow patients. Alternatively, intravenous glucose solution may be given through a large vein.

Overall, understanding the causes, features, and management of hypoglycaemia is crucial for individuals with diabetes or other conditions that increase the risk of low blood sugar levels. Prompt and appropriate treatment can help prevent complications and improve outcomes.

Differentiating Hypoglycaemia from Diabetic Ketoacidosis in Critically Ill Patients

When assessing a critically ill patient, it is important not to forget the E in the ABCDE algorithm. In the case of a woman presenting acutely, with a normal respiratory rate, it is more likely that she is hypoglycaemic rather than experiencing diabetic ketoacidosis (DKA). To confirm this, it is essential to check her glucose or blood sugar levels and then administer glucose as necessary.

It is crucial to differentiate between hypoglycaemia and DKA as the treatment for each condition is vastly different. While hypoglycaemia requires immediate administration of glucose, DKA requires insulin therapy and fluid replacement. Therefore, a correct diagnosis is essential to ensure the patient receives the appropriate treatment promptly.

In conclusion, when assessing a critically ill patient, it is vital to consider all aspects of the ABCDE algorithm, including the often-overlooked E for exposure. In cases where a patient presents acutely, with a normal respiratory rate, it is essential to differentiate between hypoglycaemia and DKA by checking glucose levels and administering glucose or insulin therapy accordingly.

The patient is exhibiting symptoms consistent with a state of elevated cortisol levels, known as Cushing syndrome. These symptoms include recent weight gain, a round face (moon face), abdominal striae, high blood pressure, and truncal obesity. Cushing syndrome can have various causes, including the use of glucocorticoids or an ectopic ACTH secretion.

Elevated cortisol levels can lead to an increase in blood glucose levels, putting individuals at risk for hyperglycemia and diabetes. Cortisol can also suppress the immune system, inhibiting the production of prostaglandins, leukotrienes, and interleukin-2, and decreasing the adhesion of white blood cells. Additionally, cortisol can up-regulate alpha-1-adrenoceptors on arterioles, resulting in high blood pressure. High cortisol levels can also decrease osteoblast activity, leading to weakened bones, and reduce fibroblast activity and collagen synthesis, resulting in delayed wound healing. The abdominal striae seen in patients with high cortisol levels are typically due to decreased collagen synthesis.

Causes of Cushing’s Syndrome

Cushing’s syndrome is a condition that can be caused by both endogenous and exogenous factors. However, it is important to note that exogenous causes, such as the use of glucocorticoid therapy, are more common than endogenous ones. The condition can be classified into two categories: ACTH dependent and ACTH independent causes.

ACTH dependent causes of Cushing’s syndrome include Cushing’s disease, which is caused by a pituitary tumor secreting ACTH and producing adrenal hyperplasia. Ectopic ACTH production, which is caused by small cell lung cancer, is another ACTH dependent cause. On the other hand, ACTH independent causes include iatrogenic factors such as steroid use, adrenal adenoma, adrenal carcinoma, Carney complex, and micronodular adrenal dysplasia.

In some cases, a condition called Pseudo-Cushing’s can mimic Cushing’s syndrome. This is often caused by alcohol excess or severe depression and can cause false positive results in dexamethasone suppression tests or 24-hour urinary free cortisol tests. To differentiate between Cushing’s syndrome and Pseudo-Cushing’s, an insulin stress test may be used.